Pioneering treatments for Glaucoma, NAION, and Diabetic Retinopathy to prevent blindness
Pioneering treatments for Glaucoma, NAION, and Diabetic Retinopathy to prevent blindness
Glaucoma is the leading cause of blindness and is often related to high intraocular pressure. However, over 10% have progressive visual loss despite optimal intraocular pressure lowering. Our drugs are proven to reduce visual loss in animal studies. Non-human primate studies are pending, and human trials will begin in 2025.
Diabetic Retinopathy (DR) is caused by damage to blood vessels in the retina of diabetic patients leading to vision loss. Our DR therapeutics are in the early stages of pre-clinical studies
MD Anderson Cancer Center
Marion Merrell Dow, Neurocrine,
Cytovia, Molecular Therapeutics,
Molecular Imaging Research
NuFund Venture Group
Founder – Gateway Genomics
NuFund Venture Group, Band of Angels, Life Science Angels
Registered Patent Attorney
Professor, Department of Ophthalmology
University of Colorado School of Medicine
Glaucoma Expert
Associate Professor, Ophthalmology
University of Colorado School of Medicine
Walgreens Boots Alliance
NuFund Venture Group
Azura Ophthalmics Limited, CEO
EBC Consulting Pty Limited, Founder
Locanabio, Inc.
Board Certified Anesthesiologist
The Pre-seed raise is fully subscribed and has officially been closed
The Seed raise will open in mid 2024
Subscribe to the mailing list to be notified.
Nufund Venture Group highlights Eyegenex's innovative breakthroughs in ophthalmic care
Dr. Robert Rothman engages in a captivating dialogue with Dr. Prasad Sunkara, CEO of Eyegenex.
Contact to receive updates, news, and more.